Investment treaty disputes in the life sciences Industry
In its global scale and economic impact, the life sciences industry presents unique considerations for investment treaty arbitrations. The covid-19 pandemic...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
CRA’s life sciences arbitration support is grounded in a comprehensive, insiders’ understanding of pharmaceutical, biotechnology, medical device, and diagnostic markets. For more than 25 years, we have consulted directly with major life science companies, law firms, and regulatory agencies around the globe. This deep industry knowledge is complemented by our extensive experience in complex litigation. CRA’s involvement has helped our clients solve their most challenging strategic problems and resolve their most contentious disputes.
Group Vice President and Life Sciences Practice Leader
Boston
+1-617-425-3357 gbell@crai.comIn its global scale and economic impact, the life sciences industry presents unique considerations for investment treaty arbitrations. The covid-19 pandemic...
In its global scale and economic impact, the life sciences industry presents unique considerations for investment treaty arbitrations. Recently, the COVID-19...